Lucid Diagnostics Inc. - Common Stock, par value $0.001 per share (LUCD) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2021 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
LUCD on Nasdaq
Shares outstanding
137,162,201
Price per share
$1.09
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
35,149,381
Total reported value
$35,503,868
% of total 13F portfolios
0%
Share change
+16,212,809
Value change
+$16,337,031
Number of holders
83
Price from insider filings
$1.09
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Lucid Diagnostics Inc. - Common Stock, par value $0.001 per share (LUCD) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
PAVmed Inc. 28% $39,205,072 38,816,903 PAVmed Inc. 09 Oct 2025
Ayrton Capital LLC 2% $1,596,645 1,200,485 Ayrton Capital LLC 31 Dec 2024

As of 30 Sep 2025, 83 institutional investors reported holding 35,149,381 shares of Lucid Diagnostics Inc. - Common Stock, par value $0.001 per share (LUCD). This represents 26% of the company’s total 137,162,201 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Lucid Diagnostics Inc. - Common Stock, par value $0.001 per share (LUCD) together control 25% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
VANGUARD GROUP INC 3.3% 4,523,997 +9.6% 0% $4,569,237
MASTERS CAPITAL MANAGEMENT LLC 2.9% 3,999,273 +47% 0.65% $4,039,266
BlackRock, Inc. 2.7% 3,669,292 +1.4% 0% $3,705,985
Two Seas Capital LP 2.2% 3,000,000 0.18% $3,030,000
AWM Investment Company, Inc. 2.2% 2,990,500 0.28% $3,020,405
Ghisallo Capital Management LLC 2.2% 2,960,066 0.1% $2,989,667
Aberdeen Group plc 1.8% 2,500,000 0% $2,525,000
GEODE CAPITAL MANAGEMENT, LLC 1.2% 1,674,173 +6.1% 0% $1,691,131
Alyeska Investment Group, L.P. 1% 1,383,116 +87% 0% $1,396,947
PERKINS CAPITAL MANAGEMENT INC 0.82% 1,127,000 1% $1,138,270
STATE STREET CORP 0.74% 1,017,787 +63% 0% $1,027,965
LUMINUS MANAGEMENT LLC 0.67% 912,805 +15% 0.83% $921,933
WELLS FARGO & COMPANY/MN 0.52% 714,313 +215% 0% $721,456
GOLDMAN SACHS GROUP INC 0.41% 560,154 +81% 0% $565,756
NORTHERN TRUST CORP 0.37% 503,745 -4.8% 0% $508,783
Sunbelt Securities, Inc. 0.28% 383,999 +357% 0.03% $387,839
Lido Advisors, LLC 0.28% 383,082 0% 0% $386,913
FIRST MANHATTAN CO. LLC. 0.24% 323,450 0% 0% $326,685
RENAISSANCE TECHNOLOGIES LLC 0.21% 293,633 +21% 0% $296,569
Bank of New York Mellon Corp 0.15% 205,889 +31% 0% $207,948
XML Financial, LLC 0.13% 178,795 0% 0.01% $180,583
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.13% 174,868 0% 0% $176,617
UBS Group AG 0.11% 145,244 +117% 0% $146,696
LPL Financial LLC 0.1% 141,179 +366% 0% $142,591
BARCLAYS PLC 0.07% 100,276 -16% 0% $101,279

Institutional Holders of Lucid Diagnostics Inc. - Common Stock, par value $0.001 per share (LUCD) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 3,482,032 $3,795,415 +$1,021,046 $1.09 5
2025 Q3 35,149,381 $35,503,868 +$16,337,031 $1.01 83
2025 Q2 18,928,571 $21,732,070 +$10,810,145 $1.15 70
2025 Q1 9,361,697 $13,942,565 +$9,083,709 $1.49 47
2024 Q4 3,301,334 $2,700,118 +$681,674 $0.82 31
2024 Q3 2,453,404 $1,999,216 +$373,764 $0.82 27
2024 Q2 1,993,582 $1,635,840 -$60,859 $0.82 31
2024 Q1 2,071,200 $1,687,992 +$173,028 $0.81 26
2023 Q4 1,747,190 $2,463,380 -$132,319 $1.41 23
2023 Q3 1,915,159 $2,240,076 +$59,719 $1.17 23
2023 Q2 1,863,743 $2,590,935 +$131,895 $1.39 16
2023 Q1 1,768,504 $2,486,590 -$200,456 $1.40 18
2022 Q4 1,914,916 $2,603,465 -$579,811 $1.36 21
2022 Q3 2,303,350 $3,522,489 -$263,904 $1.53 20
2022 Q2 2,455,369 $5,552,000 -$914,258 $2.26 23
2022 Q1 2,705,630 $9,090,000 -$2,655,787 $3.36 30
2021 Q4 3,308,904 $17,765,000 +$14,803,000 $5.37 35